Repeats in the kringle IV encoding domains in the Apo(a) gene and serum lipoprotein(a) level do not contribute to the risk for avascular necrosis of the bone (AVN) in pediatric acute lymphoblastic leukemia
Avascular necrosis of the bone (AVN) or osteonecrosis is a potentially disabling complication of the treatment of childhood ALL. The reported incidence of symptomatic AVN in pediatric ALL is 4-12.5% with a higher incidence in older children.
1 AVN mostly affects the weight bearing joints resulting in progressive joint damage, sometimes necessitating total joint replacement. Symptoms consist of pain, limited range of motion, limping, joint destruction following bone collapse and arthritis.
The pathogenesis of AVN is multifactorial. In ALL patients the use of corticosteroids and methotrexate is thought to contribute to the development of AVN. 2 However, the difference in the occurrence and severity of symptomatic AVN between pediatric ALL patients treated according to one and the same treatment protocol suggests differences in susceptibility based on genetic variation.
Familial occurrence of bone marrow edema syndrome (early phase of AVN) has been described to be associated with elevated levels of Lipoprotein(a) (Lp(a)).
3 Lp(a) is a complex of low-density lipoprotein (LDL) and a high molecular weight glycoprotein called apolipoprotein(a) (Apo(a)). Plasma Lp(a) concentration shows wide variation among individuals. This variation in concentration of Lp(a) is inheritable and inversely related to the number of kringle IV repeats in the gene for apo(a) (LPA) 4 on chromosome 6. The number of repeats of kringle IV type 2 in the LPA gene determines the size of the Apo(a) protein, which in its turn effects the plasma concentration of Lp(a). 4 The influence of lipid profiles or LPA kringle IV repeats on the occurrence of AVN in pediatric ALL has never been investigated. We hypothesized that children developing symptomatic AVN during ALL therapy might have a lower number of kringle IV repeats in the LPA gene, and consequently have higher Lp(a) levels, as compared to those who do not develop AVN and that those children who develop AVN during ALL treatment. We studied lipid status, with a special focus on Lp(a) in children with ALL with and without symptomatic AVN.
Our study group consisted of 10 children who developed symptomatic AVN during ALL treatment (five male/five female) with a median age of 15.0 years and 14 children who did not develop AVN (six male/eight female) with a median age of 6.6 years. Symptomatic AVN was defined as pain of the extremities, not related to treatment with vincristine and confirmed by the typical findings on MRI. Furthermore, kringle IV repeats were determined in a control group of 11 healthy adult Caucasian subjects (three male/eight female; median age 33.7 years). The ALL patients were treated in our hospital according to the Dutch national treatment protocol (DCOG-ALL9) which consists of induction therapy, followed by HD-MTX and maintenance in which dexamethasone is given in 2-week repetitive courses during 2 years. HR patients receive two blocks of intensification therapy between HD-MTX and maintenance. The AVN group consisted of two patients with T-ALL and nine patients with precursor-B ALL; four patients were treated according to the high-risk protocol (HR) and seven according to the non-high risk protocol (NHR). In the non-AVN group five patients had T-ALL and nine patients precursor-B ALL; six patients were treated according to the HR and eight according to the NHR.
DNA was isolated from peripheral blood mononuclear cells (PBMC's) in blocks of 1% incert agarose (FMC Bioproducts, Rockland, USA). Cells were subsequently lysed by incubating the agarose blocks in 5 volumes of 0.5 M EDTA, 1% sodium-Nlauroyl sarcosine (pH ¼ 9.5), 0.5 mg/ml proteinase K (Roche Diagnostics, Almere, The Netherlands) at 501C overnight. DNA was digested by incubating the blocks for 6 h at 371C in the restriction enzyme buffer supplemented with 1.0 mM DTT, 2.0 mM spermidine, 0.3 mg/ml BSA and 40 units KpnI restriction enzyme. DNA was analyzed with pulsed field gel electrophoresis (PFGE), using a 1.2 Kb Kpn1-BamH1 intron fragment from the Apo (a) gene (kindly provided by Professor Dr G Utermann) labeled with (a-32 P)dCTP (ICN, 111TBq/mmol). Kringle IV repeats numbers were calculated from the DNA fragment size relative to the DNA size standards. In addition, plasma lipids (Lp(a), apo-A1, Apo-B, LDL, HDL, triglycerides and cholesterol) were determined in both ALL patients with AVN and ALL patients without AVN.
ALL-patients with symptomatic AVN had a median Lp(a) serum level of 0.086 g/l (range o0.02-0.848 g/l), whereas patients without AVN had a median Lp(a) level of 0.066 g/l (range o0.020-0.362 g/l; P ¼ 0.79). In the healthy adult controls median Lp(a) level was 0.105 g/l (range o0.020-0.680 g/l). All levels were within normal ranges and no significant differences were found between the three groups.
In Figure 1 the sum of kringle IV repeats in both alleles of the LPA gene is shown for children with AVN, children without AVN and healthy controls. Again, no significant differences were found between the three groups. We did find a significant inverse relation between Lp(a) serum levels and the sum of the repeats of allele 1 and allele 2 of the LPA gene (r ¼ À0.36; P ¼ 0.05) as was described previously by others in adults. 5 Although high Lp(a) serum levels have been associated with familiar AVN, 3 a large variation in Lp(a) protein levels was observed in individuals with the same number of kringle IV repeats. 4 We did not find higher Lp(a) levels in pediatric ALL Letters to the Editor patients with symptomatic AVN, which is consistent with our finding that AVN was not related with the number of kringle IV repeats.
So far most studies that reported an association between Lp(a) levels and AVN were performed in adults. In adults, Lp(a) inhibits the activation of plasminogen and the conversion of plasminogen to plasmin. It is thought that this reduction in fibrinolytic activity plays a role in the pathogenesis of thromboembolic processes in adult patients with increased serum levels of Lp(a). 4 To our knowledge, no studies of Lp(a) and AVN have been performed in childhood ALL patients. In children without leukemia reports on the association between Lp(a) and idiopathic osteonecrosis, show contradictory results, 6, 7 that is, Glueck et al. 6 found higher Lp(a) levels in patients with LeggPerthes disease, whereas Posan et al. 7 did not. Apart from the role of Lp(a) in the development of AVN, hyperlipidemia has been suggested as an etiological factor of osteonecrosis. 8 Motomura et al. showed that treatment with lipid lowering medication (probucol) prevented steroid induced AVN in rabbits. 8 We found no significant differences in cholesterol, HDL, LDL, triglycerides and apo-B levels between pediatric ALL patients with or without symptomatic AVN (Table 1 ). There were no differences in LDL/HDL ratios or apo-B/apo-A1 ratios between patients with or without AVN. In contrast to the studies in rabbits, we did not assess lipid levels during corticosteroid therapy but 5 weeks later just before the next block of dexamethasone therapy. This might explain the normal lipid levels in our cohort of patients. It might be that like in the animal studies, increased lipid levels during corticosteroid administration may play a role in the development of therapy related AVN.
Still, individual differences in vulnerability with respect to developing AVN in ALL suggests a role for genetic variation. Other genetic polymorphisms might be associated with AVN in pediatric ALL. Indeed, Relling et al. showed in a group of pediatric ALL that polymorphisms in the vitamin D receptor and thymidylate synthase are independent predictors for osteonecrosis. 9 Also, other polymorphisms have been suggested to play a role in the development of AVN, like polymorphisms in the folate pathway (e.g. methylenentetrahydrofolate reductase) and polymorphisms in cytochrome P 450 . LPA polymorphisms have not been analyzed in these studies.
In conclusion, this is the first study that investigated the role of lipid metabolism in developing symptomatic AVN during treatment for pediatric ALL. Levels of triglycerides, cholesterol, LDL, HDL, Apo-A1 or Apo-B do not differ between patients with and without AVN. Moreover, Lp(a) levels and the number of kringle IV repeats of the LPA gene do not contribute to an increased risk of symptomatic AVN in children treated for ALL. Letters to the Editor
